Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Amortizatization of Intangibles (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Amortizatization of Intangibles for 13 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortizatization of Intangibles fell 34.1% year-over-year to $1.8 million, compared with a TTM value of $7.2 million through Dec 2025, down 37.6%, and an annual FY2025 reading of $7.2 million, down 37.6% over the prior year.
  • Amortizatization of Intangibles was $1.8 million for Q4 2025 at Agios Pharmaceuticals, up from -$652000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $14.9 million in Q4 2021 and bottomed at -$3.8 million in Q2 2022.
  • Average Amortizatization of Intangibles over 5 years is $2.4 million, with a median of $2.6 million recorded in 2022.
  • The sharpest move saw Amortizatization of Intangibles tumbled 1220.63% in 2021, then surged 562.92% in 2022.
  • Year by year, Amortizatization of Intangibles stood at $14.9 million in 2021, then plummeted by 82.76% to $2.6 million in 2022, then grew by 7.41% to $2.8 million in 2023, then fell by 3.38% to $2.7 million in 2024, then plummeted by 34.1% to $1.8 million in 2025.
  • Business Quant data shows Amortizatization of Intangibles for AGIO at $1.8 million in Q4 2025, -$652000.0 in Q3 2025, and $3.1 million in Q2 2025.